Heterogeneity among human collagenases demonstrated by monoclonal antibody that selectively recognizes and inhibits human neutrophil collagenase by unknown
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The interstitial collagenases are a group of metalloproteinases that are capable 
of degrading the interstitial collagens (types I, II, and III). Enzymes of this class 
have been isolated from skin fibroblasts (1), synovial cells (2), macrophages (3), 
and neutrophils  (4).  Despite  the heterogeneity among the  cells' origins,  these 
enzymes cleave native collagen molecules at the same amino acid residues. The 
best-characterized of these enzymes are those derived from skin fibroblasts and 
synovial cells. Both of these collagenases are released from the cell in a latent, 
proenzyme form and can be converted to their active species by organic mercurial 
compounds or by limited proteolysis with trypsin (as well as other proteinases) 
(1,  5).  These  enzymes are  more active against  type  III'than  type  I  collagen. 
Extensive analysis of these two collagenases have indicated that they are nearly 
identical. 
Human neutrophil collagenase (HNC) l is not nearly as well-characterized even 
though it was one of the first to be described. This is in part due to the difficulty 
of purification and to the relative instability of the enzyme. Nevertheless, there 
are several reports suggesting that this collagenase may be quite different from 
those from skin and synovial cells. HNC has been reported to be slightly larger 
by molecular weight estimates (6), to degrade type I collagen more rapidly than 
type  III  (7),  and  to  be  resistant  to  inactivation  by  a2-macroglobin  (8).  The 
immunological data  comparing  HNC  with  other  collagenases,  however,  have 
been controversial.  Bauer et al.  (9)  found synovial,  gingival, and granulocyte 
collagenase to cross-react identically with human skin collagenase in an immu- 
noassay  using  antibody  to  skin  collagenase.  By  contrast,  Woolley  et  al.  (10) 
showed no reaction between granulocyte collagenase and antibody to rheumatoid 
synovial collagenase. Previous reports of polyclonal antibodies against neutrophil 
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collagenase have not addressed whether the neutrophil enzyme is distinct from 
the skin and synovial collagenases. In this report, we have shown human neutro- 
phil collagenase to be  immunologically distinct from human synovial and skin 
collagenase using a  rigidly defined monoclonal antibody. The recognition that 
neutrophil collagenase is distinct from other collagenases underlines the impor- 
tance of precise identification of the source of the collagenase present in inflam- 
matory  diseases  such  as  rheumatoid  arthritis  (11)  and  idiopathic  pulmonary 
fibrosis (11) in our understanding of the pathogenesis of these diseases. 
Materials and Methods 
Leukocyte Isolation and Stimulation.  Leukocytes were  isolated from whole blood  by 
dextran  sedimentation,  washed  three  times  with  phosphate-buffered  saline  (0.02  M 
phosphate, 0.15 M NaCI, pH 7.4), followed by hypotonic iysis of contaminating erythro- 
cytes according to the method of Boyum (13). The leukocyte fraction was resuspended at 
a  concentration of 107 cells/ml in  Hanks' balanced salt solution (Gibco  Laboratories, 
Grand Island, NY) containing Ca  ++ and Mg  ÷+ and phorboi myristate acetate (PMA) (50 
ng/ml; Sigma Chemical Co., St.  Louis, MO) to induce granule release (14).  After a  15 
min incubation at 37°C, the cells were removed by centrifugation. Phenylmethyisulfonyl 
fluoride was added to a final concentration of 0.001 M and the supernatants were frozen. 
In some experiments, the mononuclear cells were separated from the granulocytes by 
centrifugation on Ficoli-Hypaque (13). After Ficoil-Hypaque centrifugation, the granu- 
locytes were  further purified by dextran  sedimentation and  washed with phosphate- 
buffered saline and the erythrocytes were removed by hypotonic lysis. Granule release 
was induced as described above. 
Preparation of the Immunogen.  After dialysis against 0.01  M Tris-HC1, 0.005 M CaCI2, 
0.02% NaN3 at pH 8.3, the leukocyte supernatants were applied to a column of DEAE 
Affi-Gel Blue. The enzyme was eluted with a gradient of 0-0.7 M NaC1 in 0.01  M Tris- 
HCI, 0.005  M CaCI2, pH 8.3. The peak of collagenolytic activity was pooled, dialyzed 
against 0.05 M Tris-HCl, 0.5 M NaCl, 0.005 M CaCI~, 0.02% NaNs, pH 7.6, concentrated 
by pressure dialysis, and chromatographed on an ACA 34 gel filtration column. Those 
fractions showing collagenase activity were pooled, dialyzed against phosphate-buffered 
saline,  concentrated by pressure dialysis, and frozen for use as an immunogen and an 
antigen in the enzyme-linked immunosorbent assay (ELISA). 
Hybridoma Selection and Screening.  Mice were immunized intradermally with 20 #g of 
partially purified collagenase from the gel filtration column in complete Freund's adjuvant. 
30 d after the initial immunization, they received an intravenous boost with the antigen 
in saline. 3 d after the secondary immunization, the spleen cells were fused with the mouse 
myeloma line SP 2/0 using polyethylene glycol (PEG; Aldrich Chemical Co., Milwaukee, 
WI) as previously described (15). 
Hybrids were assayed for antibody activity using an ELISA against the immunogen. 
Cultures positive  by ELISA were further assayed for inhibition of enzyme activity in a 
collagen fibril assay.  For this assay, the culture medium was supplemented with serum 
that had been acid-treated to inactivate a2-macroglobulin. Cultures were subcloned two 
additional times in methylcellulose. 
Immunological Analysis.  Antibodies were assayed in an ELISA (16,  17). The wells of a 
microtiter plate were coated with 100 #! of partially purified neutrophil collagenase (5 
#g]mi) in 0.05 M Tris, 0.15 M NaCI, pH 7.6 at 4°C overnight. Excess protein binding 
sites were blocked with the addition of 50 #1 of 1% bovine serum albumin (BSA) with an 
additional incubation of 1 h at room temperature followed by five washes with ELISA 
buffer (0.05 M Tris, 0.15 M NaCI, 0.05% Tween 20). 100 #1 of culture medium or ascites 
fluid diluted in ELISA buffer containing 0.1% BSA was incubated on the plates for 2 h 
at room temperature and the plates were again washed five times with ELISA buffer. A 
peroxidase-conjugated goat anti-mouse immunoglobulin (100 #1; Cappel  Laboratories, 
Cochranville, PA) at a  1:1,500 dilution in 0.1%  BSA in ELISA buffer was added and HASTY ET  AL.  1457 
incubated for 1 h at room temperature. After the wells were again washed five times, 100 
tA of substrate, 0-phenylenediamine (Sigma Chemicals Co.), was added. The substrate was 
prepared by dissolving 40 mg of 0~phenylenediamine in buffer freshly prepared by mixing 
24.3 ml of 0.1  M citric acid and 25.7 ml of 0.2 M Na~HPO4 and 50 ml distilled water, 
pH 5.0.40 ~1 of 30% hydrogen peroxide was added. The reaction product was measured 
at 450 nm on a Microelisa Autoreader MR 580 (Dynatech Laboratories, Inc., Alexandria, 
VA). 
For competitive inhibition studies,  150  ttl of a  1:10,000 dilution of ascites  fluid was 
preincubated at 37°C for I  h with an equal volume of varying amounts of collagenase 
before incubation on the ELISA plate. The human neutrophil collagenase used as a solid 
phase and competitive antigen in these studies was isolated from the monocional antibody 
affinity column and had a concentration of 312 ng/ml. 
Immunoaffinity Column.  Hybridoma cultures  were  grown  in  serum-free  Dulbecco's 
minimum essential medium (MEM) supplemented with nonessential amino acids, penicil- 
lin, streptomycin, and insulin (5 ~g/ml), transferrin (5 ~g/ml), and selenium (5 ng/ml) 
(ITS-Premix; Collaborative Research,  Inc.,  Waltham,  MA).  The  culture supernatants 
were pooled, dialyzed against 0.5 M NaCI, 0.1  M NaHCOs, pH 8.2, and concentrated 
10-fold by pressure dialysis. The serum-free concentrate was then covalently linked to 
cyanogen bromide-activated Sepharose (Bio-Rad Laboratories, Rockville Centre, NY). 
Crude neutrophil supernatants were dialyzed into 0.05 M Tris, 0.15 M NaCI,  0.005 M 
CaCI2, 0.02% NAN3, pH 7.6 and chromatographed on the antibody affinity column. The 
columns were washed with 20 vol of buffer and eluted with 6-8 vol of 3.5 M sodium 
thiocyanate (NaSCN).  After dialysis of the eluate against the starting buffer, all fractions 
were assayed for collagenase activity using soluble type I collagen as substrate. 
Collagenase Assay.  Type I  collagen was extracted from fetal calf skin and purified 
by the method of Glimcher et al. (18).  The purified collagen was radiolabeled using 
14  [  C]acetic anhydride (19). Collagenolytic  activity was measured by either determining the 
release of radioactivity  from reconstituted collagen fibrils (20) at 37 °C or by the incubation 
of the enzyme with soluble collagen at 25°C. In the soluble assays, 0.05 M arginine was 
included to prevent fibril formation and the degradation of collagen was assessed  by 
separation of the reaction products on 7.5% polyacrylamide gels. Assays were run in the 
presence and absence of 1 mM aminophenyi mercuric acetate (APMA) to determine the 
amount of latent enzyme present (21). In experiments where the inhibitory activity of the 
monocional antibody was examined, the hybridoma culture supernatants were preincu- 
bated with neutrophil supernatants for  1 h  at room temperature before the assay for 
coilagenolytic activity. 
Sodium Dodecyl Sulfate Gels.  Electrophoresis was performed according to the method 
of Laemmli (22)  using a  Bio-Rad slab  gel  apparatus.  Gels were  stained with 0.25% 
Coomassie Brilliant Blue R-250  in 45%  methanol,  7%  acetic acid overnight at room 
temperature and destained in 10% methanol, 7% acetic acid. 
Protein Determination.  Protein concentration was assayed using the Bio-Rad Protein 
Assay Kit (Bio-Rad Laboratories). 
Human Mesenchymal Collagenases.  Purified human skin collagenase was provided by 
Dr. George Stricklin and Dr. Arthur Eisen, Washington University School of Medicine, 
St. Louis, MO. Purified human rheumatoid synovial collagenase was obtained from Carol 
Vater and Dr. E. D. Harris, Jr., Dartmouth Medical School, Hanover, NH. 
Results 
Collagenolytic Activity  in  Enriched  Mononuclear  (MNL)  and  Polymorphonuclear 
(PMNL)  Leukocyte Fractions.  Previous  studies  have  suggested  that  the  MNL 
fraction is a poor source of collagenase and that this collagenolytic activity is not 
stored but rather requires new protein synthesis. Thus, the contribution of MNL 
to the collagenolytic activity secreted during this short incubation period should 
be minimal. However, to ascertain that the MNL in the crude leukocyte prepa- 1458  HETEROGENEITY  AMONG  COLLAGENASES 
rations routinely used were not the source of the enzyme generated, the MNL 
and  PMNL  fractions  were  separated  by  isopyknic  centrifugation  on  Ficoll- 
Hypaque. Both cell populations were resuspended at 107 cells/ml and stimulated 
with 50 ng/ml PMA for 15 min at 37°C. \The supernatants from these cultures 
were tested for collagenolytic activity by incubating equal amounts of culture 
supernatant with reconstituted collagen fibril for  18 h at 37°C in the presence 
and absence  of APMA.  No  collagenolytic activity was  noted in  MNL  culture 
supernatants  even  in  the  presence  of APMA  (Table  I).  In  contrast,  culture 
supernatants  from  PMA-stimulated  PMNL  showed  significant  coilagenolytic 
activity in the presence but not in the absence of APMA. These results indicate 
that  the  collagenolytic  activity  generated  from  the  leukocyte  fraction  after 
stimulation by PMA was derived from PMNL and was present in latent form. 
Thus, the immunogen and screening antigen were derived from the PMNL. 
Characterization of Monoclonal Antibody with  Inhibitory Activity Against  HNC. 
When colonies of hybrid cells were assayed by the ELISA, six of the wells reacted 
with the immunogen and were screened further for their ability to inhibit the 
collagenolytic activity of crude neutrophil supernatant against a  collagen fibril 
substrate. Medium from only one showed significant and reproducible inhibition 
of collagenase activity. This clone was then recloned twice. The antibody secreted 
by this clone was used for all further experiments. 
Although the  inhibition of enzyme activity was suggestive evidence that an 
antibody to neutrophil collagenase had been isolated, the possibility existed that 
the antibody was interfering with the activation of latent collagenase instead of 
directly inhibiting the enzyme's action against the collagen substrate. To differ- 
entiate between these modes of inhibition, the culture medium containing the 
antibody was added either to neutrophil supernatant containing a latent enzyme 
or to the same sample with APMA present to activate the enzyme. The enzyme 
without APMA resulted in minimal lysis as compared with the sample containing 
enzyme plus APMA,  as  would be  expected from a  latent  enzyme (Table  II). 
Antibody added after APMA activation of the latent enzyme inhibited enzyme 
activity equally as well as antibody added before APMA activation. These results 
indicate  that  the  antibody  inhibition  of  collagenase  activity  was  due  to  its 
interaction  with  the  enzyme directly and  not  to any  effect  on  the activation 
process. 
The above studies suggested that the neutralizing monoclonal antibody was 
specific for activated neutrophil collagenase, but did not show if the antibody 
would bind  latent collagenase as well.  Therefore,  the antibody was  linked to 
TABLE  I 
Collagenase Activity of Mononudear vs. Granulocyte  Fraction 
Percent total  Percent collagen lysis 
Fraction  cells  -APMA  +APMA 
Mononuclear  100  0  0 
Granulocyte  95  0.5  69.9 
* Each sample contained  100 #g of collagen. Percent lysis was calculated 
as [counts released/counts released by bacterial collagenase] x  100 after 
subtraction from all values of the counts released by I 0 #g of trypsin. HASTY ET  AL. 
TABLE II 
Antibody Inhibition of Human Neutrophil Collagenase: Inhibition of Enzyme Activity 
vs. Inhibition of Activation of Latent Collagenase 
1459 
Preactivation anti-  Postactivation anti-  Percent  collagen 
Sample  body addition  APMA  body addition  lysis* 
1  -  -  -  13.0 
2  -  +  -  38.5 
3  +  +  -  15.3 
4  -  +  +  16.2 
* Collagen fibrils (100 #g/sample) were incubated with the enzyme overnight at 37°C. 
FIGURE 1.  Type I collagen after digestion with neutrophil coilagenase with (+) or without 
(-) APMA to effect activation. (a) Crude enzyme, (b) crude enzyme after passage over the 
antibody  column, and (c) subsequent  elution  of the enzyme  from antibody  column with NaSCN. 
cyanogen bromide-activated Sepharose, and crude neutrophil supernatants  con- 
taining latent collagenase were chromatographed.  Analysis of these supernatants 
for enzyme activity by incubation with substrate in the absence and presence of 
APMA indicated that the enzyme applied to the affinity columns was predomi- 
nantly in the latent form (Fig.  1 a). When applied to the column, the majority of 
the enzyme activity was bound. The small amount of activity seen in the material 
appearing  in  the  initial  wash-through  (Fig.  1 b)  appeared  to  be  due  to  the 
overloading of the column because, upon rechromatography, all of this material 
bound to the column  (data not shown).  After elution with  3.5  M  NaSCN,  the 
collagenase was active even in the absence of APMA (Fig.  1 c). Taken together 
with  the  inhibition  studies,  these results  indicate  that  the antibody recognized 
both latent and active forms of neutrophil collagenase. 
Cross-reactivity with Human Mesenchymal Collagenases.  Although the immunoab- 
sorbent column  suggested that  the monoclonal antibody was capable of recog- 
nizing  both  latent  and  active collagenase,  its  value as a  probe to differentiate 
neutrophii  collagenase  from  other  human  collagenases  remained  to  be deter- 
mined.  The  cross-reactivity  of the  antibody  was  assayed  by two  methods  (a) 
screening for inhibition  of enzyme activity, and (b) using the ELISA to test for 1460  HETEROGENEITY AMONG COLLAGENASES 
the ability of other human collagenases to competitively inhibit the antibody's 
reaction with neutrophil collagenase. 
To  test for inhibition of enzyme activity against other  human collagenases, 
culture medium from hybrid cells grown in acid-treated serum was preincubated 
with human skin collagenase, human rheumatoid synovial collagenase, or crude 
human neutrophil collagenase before incubation in a  collagen fibril assay. The 
collagenase  activity  of each  preparation  had  been  previously  calibrated  and 
standardized  to  result  in  20-50%  of total  lysis.  As  shown  in  Table  III,  only 
neutrophil collagenase was substantially inhibited in the presence of the antibody. 
However, the small amount of inhibition of human rheumatoid synovial colla- 
genase  made  it  necessary to  define  the  immunological cross-reactivity.  Using 
each of the other collagenases in a competitive inhibition ELISA against affinity- 
purified neutrophil collagenase as the solid-phase antigen, no cross-reactivity of 
the  monoclonal  antibody  was  seen  with  human  skin  or  rheumatoid  synoviai 
collagenase even with quantities of the enzymes that were  10-fold greater than 
TABLE III 
Inhibition of Various Human Collagenases by Monoclonal Antibody 
Enzyme activity  after preincuba- 
Enzyme  tion with antibody in acid- 
treated serum medium (percent 
of control)* 
Human skin collagenase  101 
Human rheumatoid synovial  collagenase  83 
Human neutrophil collagenase  47 
* Controls were enzyme that had been preincubated with medium containing 
acid-treated serum alone. Human skin collagenase  lysed 22.1/zg collagen total, 
human rheumatoid synovial  collagenase  lysed  25.3 #g collagen  total, and human 
neutrophil collagenase  lysed 45.6 ~tg collagen total. 
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FIGURE 2.  Competitive inhibition of monoclonal antibody l lb. 1 with human neutrophil 
collagenase (HNC), skin collagenase (HSKC), or rheumatoid synovial collagenase (HRSC) 
against HNC as the solid-phase  antigen. HASTY  ET  AL.  1461 
that of affinity-purified neutrophil collagenase (Fig. 2). By contrast, 80 ng/ml of 
neutrophil collagenase gave 100% inhibition in the ELISA. Therefore, neutro- 
phil collagenase is an immunologically distinctive enzyme from other human 
collagenases. 
Discussion 
The interstitial collagenase of the neutrophil has been implicated in several 
pathologic states  where collagenase activity in body fluids has been found in 
association with large numbers of neutrophils (12, 23).  Indirect evidence for a 
pathogenic role of neutrophil collagenase stems from the work of Harris et al. 
(11) who identified collagenase in rheumatoid synovial fluid that did not resemble 
~he  synovial  enzyme with  respect  to  molecular weight and  its  resistance  to 
inactivation  by  a2-macroglobulin.  However,  the  lack  of specific  probes  has 
hampered efforts  to  assess  the  role  of this  enzyme in  both  physiologic and 
pathologic processes. 
The scarcity of reports using antibody to neutrophil coilagenase may be due 
in large part to the difficulty of preparing the pure antigen. Freshly isolated 
neutrophils must be used since, unlike human skin or synovial  cells, these cells 
do not continuously synthesize this enzyme but store it in a preformed granule. 
During purification, substantial activity is lost and the specific  activity of the 
isolated enzyme is low in comparison with human skin or rheumatoid synovial 
collagenase (24). 
Two groups have reported the development of polyclonal antibodies to neu- 
trophil collagenase. Ohlsson and Olsson (25) described an antibody to neutrophil 
collagenase. However, their antibody reacts with a serine proteinase that localizes 
to the azurophil granule. This conflicts with the data that neutrophil collagenase 
is a metalloproteinase located in the specific granule (6). More recently, Christner 
and co-workers (26)  have described the isolation of a  polyclonal antibody to 
neutrophil collagenase. The cross-reactivity of their antibody to other human 
collagenases was not examined. Our antibody, however, unequivocally recog- 
nized neutrophil collagenase and shows no cross-reaction with human skin or 
human rheumatoid synovial collagenase. In view of the ability of our monoclonal 
antibody to distinguish clearly between neutrophil and mesenchymal cell colla- 
genases,  the  previous  reports  of the  larger  molecular  weight of neutrophil 
collagenase (6), and the resistance of the latter to inactivation by a2-macroglob- 
ulin (27), it is most likely that neutrophil collagenase represents a gene product 
that  is  distinct  from  the  other mesenchymal collagenases.  Its  mechanisms of 
activation and inhibition as well as those secretagogues that promote its release 
may well be different from those previously described for mesenchymal collagen- 
ases. 
Summary 
The heterogeneity of human collagenases has been examined using a mono- 
clonal antibody to neutrophil collagenase. This antibody inhibited collagenase 
activity and, when covalently coupled to Sepharose, bound both latent and active 
enzyme. Although human neutrophil collagenase was inhibited by the antibody, 1462  HETEROGENEITY  AMONG  COLLAGENASES 
the activity of human  skin and rheumatoid  synovial collagenase  was not signifi- 
cantly diminished in the presence of the antibody, Competitive inhibition studies 
also differentiated  between these coilagenases,  Only human neutrophil  collagen- 
ase  effectively blocked  the  antibody  in  a  competitive  enzyme-linked  immuno- 
sorbent  assay  while  skin  and  rheumatoid  synovial  collagenase  again  failed  to 
interact  with the antibody.  The unequivocal recognition  of neutrophil  collagen- 
ase as an  immunologically  distinct  entity  from other  collagenases  supports  the 
hypothesis that neutrophil  collagenase is a separate gene product from fibroblast 
or synovial collagenase. 
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